Antithrombotic Therapies 2019: clinical challenges and future directions

Learning objectives

The Educational Training Programme is composed of 8 sessions aiming at:

• Understanding clinically-relevant mechanisms of action (haemostatic and pharmacological) underlying the most recent and effective combined antithrombotic strategies in atherothrombotic and venous thromboembolic diseases;
• Managing atherothrombotic diseases in the chronic and acute settings, in special patient populations such as diabetic, chronic kidney disease, pregnant, obese, older and/or frail patients who remain an unmet clinical need in spite of the most recent evidence;
• Managing cardioembolic and venous thromboembolic diseases in the chronic and/or acute settings, with a special focus on cancer patients.

Programme

Faculty members list:

Working Group on Aorta & Peripheral Vascular Diseases (WGA-PVD)

1. Victor Aboyans- Chair
2. Marco De Carlo- Past Chair
3. Lucia Mazzolai- Vice Chair
4. Oliver Schlager- Treasurer
5. Marianne Brodmann
6. Christine Espinola-Klein
7. José Rodriguez-Palomares
8. Emmanuel Messas
9. Dimitrios Terentes-Printzios

Working Group on Thrombosis (WGT)

1. Dirk Sibbing- Chair
2. Bianca Rocca- Past Chair
3. Gemma Vilahur- Vice Chair
4. Andrea Rubboli- Treasurer
5. Diana Gorog
6. Rob Storey
7. Jean Philippe Collet
8. Joao Morais
9. Tobias Geisler

Special Guest: Lars Wallentin

Wednesday 12 June

13:00-14:30: Registration and lunch

14:30-14:50: Welcome message from the Working Groups Chairpersons - V Aboyans and D Sibbing

14:50-16:20: Session 1

Focus on the pathophysiology of endothelium and haemostasis / thrombosis

Chairs: V Aboyans and D Sibbing

1. Platelets and atherothrombosis - B Rocca
2. Endothelial function and biomarkers in PAD - D Terentes-Printzios
3. Factor Xa: a crossroad between coagulation and platelet - T Geisler
4. Novel targets in the coagulation pathway - D Gorog

16:20-16:45: Networking

16.45-18.15: Session 2

Antithombotic strategies in peripheral arteries

Chairs: M Brodmann and O Schlager

1. Antithrombotic strategies in carotid artery disease. Lucia Mazzolai
2. Dual antithrombotic therapies in stable patients with PAD. C Espinola-Klein
3. DAPT after peripheral revascularization. M De Carlo
4. AF & PAD: a non-random association. V Aboyans

18.30-19.00: Lecture

Antithrombotic therapies: how to assess bleeding risk and its severity?

Chairs: V Aboyans and D Sibbing

Lecturer: Lars Wallentin

19.00-20.30: Networking cocktail at the Heart House

Thursday 13 June

Morning sessions

09:00-10:30: Session 1

Combined antithrombotic strategies in CAD

Chairs: D Sibbing and T Geisler

1. Update on DAPT in the first year after ACS - R Storey
2. Dual antithrombotic strategy in stable CAD: for whom? - D Sibbing
3. Antithrombotic and antiplatelet agents one-year post-MI: how many options? - T Geisler
4. Atrial Fibrillation in stable CAD and ACS - A Rubboli

10:30-11:00: Networking

11:00-12:30: Session 2

Antithrombotic therapies in special populations

Chairs: D Gorog and M De Carlo

1. Antithrombotic therapies in acquired and congenital thrombophilic disorders? - L Mazzolai
2. Antithrombotic therapies in pregnancy - M Brodmann
3. Antithrombotic therapies in CKD - D Gorog
4. Antithrombotic therapies in the old/frail patients - E. Messas

12:30-14:00: Lunch and networking

Afternoon sessions

14:00-15:30: Session 1

Antithrombotic therapies and diabetes and/or metabolic syndrome

Chairs: J Rodriguez-Palomares and B Rocca

The haemostatic imbalance in type 2 diabetes and Metabolic Syndrome - G Vilahur Garcia
Antithrombotic strategies in diabetic patients with CAD - M De Carlo
Antithrombotic strategies in diabetic patients with PAD - C Espinola-Klein
Obesity and antithrombotic strategies in arterial and venous diseases - R Storey

15.30-16:00: Networking

16:00-17:30: Session 2

Focus on venous thromboembolism

Chairs: A Rubboli and E Messas

• Prevention of VTE: when and how? Joao Morais
• PE, DVT and SVT: current management. M Brodmann
• Long-term anticoagulation after PE/DVT: when and how? C Espinola-Klein
• Prevention and treatment of post-thrombotic syndrome. O Schlager

17:30-18:00: Networking

18:00-18:40: Debate Session

Antithrombotic strategies in asymptomatic patients: Pros and Cons

Chairs: J Morais and D Terentes-Printzios

1. Antithrombotic therapy is indicated in Primary Prevention (pro) - B Rocca
2. Antithrombotic therapy is indicated in Primary Prevention (contra) - V Aboyans
3. Rebuttal - B Rocca
4. Rebuttal - V Aboyans

18:40: Wrap up

Friday 14 June

09:00-10:30: Session 1

Focus on venous thromboembolism and cancer

20 min +10 common discussion at the end

Chairs: C Espinola-Klein and G Vilahur Garcia

1. Haemostasis and thrombosis in cancer - G Vilahur Garcia
2. Coronary and stroke events in patients with cancer - J Morais
3. Management of VTE in patients with cancer - O Schlager
4. Looking for cancer after VTE? When and how? - E. Messas

10:30-10:45: Networking

10:45-12:15: Session 2

Antithrombotic therapies and cardiovascular devices

20 min +10 common discussion at the end

Chairs: T Geisler and D Terentes-Printzios

1. PFO closure: indications and antithrombotic strategy after implantation - JP Collet
2. Left atrial appendage occlusion: indications and antithrombotic strategy thereafter - A Rubboli
3. TAVI, SAVI and antithrombotic strategies thereafter - D Sibbing
4. Aortic diseases, TEVAR, EVAR and antithrombotic strategies - J Rodriguez-Palomares

12:15-12:30: Closing remarks - V Aboyans and G Vilahur Garcia